||Recombinant Human TLR4 (Accession # O00206), fused with , was produced in Mouse myeloma cell line, NS0-derived.
|Predicted N Terminal:
||Glu24 (TLR4) & Glu17 (MD-2)
||Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein.
||Measured by its ability to inhibit LPS-induced TNF-alpha secretion by PMA-differentiated U937 human histiocytic lymphoma cells.Typically 20 µg/mL of rhTLR4/MD-2 will inhibit >60% of the TNF-alpha secretion induced by 10 ng/mL of LPS.
||Recombinant Human TLR4 has a calculated MW of 70.6 kDa (TLR4), 19.2 kDa (MD-2). In SDS-PAGE migrates as 95 kDa and 34 kDa, reducing conditions.
||>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).